Basilea Pharmaceutica Full Year 2024 Earnings: Beats Expectations

Basilea Pharmaceutica (VTX:BSLN) Full Year 2024 Results

Key Financial Results

• Revenue: CHF208.5m (up 32% from FY 2023).
• Net income: CHF77.6m (up by CHF67.1m from FY 2023).
• Profit margin: 37% (up from 6.6% in FY 2023). The increase in margin was primarily driven by higher revenue.
• EPS: CHF6.42 (up from CHF0.87 in FY 2023).

BSLN Products In Clinical Trials

• Phase I: 2.
• Phase II: 2.
• Phase III: 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Basilea Pharmaceutica Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 4.9%. Earnings per share (EPS) also surpassed analyst estimates by 45%.

The primary driver behind last 12 months revenue was the Ireland segment contributing a total revenue of CHF93.7m (45% of total revenue). Notably, cost of sales worth CHF115.8m amounted to 56% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CHF31.0m (100% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CHF15.9m. Explore how BSLN's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Europe.

Performance of the market in Switzerland.

The company's shares are up 10% from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Basilea Pharmaceutica's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.